Clinical trials: Glut1 Deficiency Syndrome
GLUT1DS1, Epilepsy
Diet Treatment Glucose Transporter Type 1 Deficiency (G1D)
Forty-five subjects receiving no dietary therapy with a proven G1D diagnosis will be enrolled. To evaluate the effect of C7 supplementation of a regular diet on a EEG activity in addition to IQ, language, working memory…
- Conditions
- GLUT1DS1, Epilepsy, Glut1 Deficiency Syndrome 1, Autosomal Recessive, Glucose Metabolism Disorders
- Trial name
- NCT03181399
- Testing
- Triheptanoin
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Texas Southwestern Medical Center
Glucose Transporter 1 Deficiency Syndrome
Treatment With UX007 for a Single Patient With GLUT1 Deficiency Syndrome
This treatment plan is intended for the use of UX007 (triheptanoin) in the treatment of a single patient with Glucose Transporter 1 (GLUT1) Deficiency Syndrome.
- Trial name
- NCT02968953
- Testing
- Triheptanoin
- Where
- United States
- Sponsor
- Jerry Vockley, MD, PhD
GLUT1 Deficiency Syndrome, GLUT1DS1
Sodium Lactate Infusion in GLUT1DS Patients
This study investigates the effect of lactate infusion on epileptic discharges on EEG and seizure frequency in glucose transporter 1 deficiency syndrome (GLUT1DS) patients.
- Conditions
- GLUT1 Deficiency Syndrome, GLUT1DS1, GLUT1DS2, Epilepsy
- Trial name
- NCT04112862
- Testing
- sodiumlactate
- Where
- Netherlands
- Volunteers
- 2 people
- Sponsor
- Radboud University Medical Center
Glucose Transporter Type 1 Deficiency Syndrome
Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS)
The primary objective of the study is to evaluate the long-term safety of UX007 in Glut1 DS participants.
- Trial name
- NCT02599961
- Testing
- UX007
- Where
- 9 sites in United States, Australia and 3 more
- Volunteers
- 15 people
- Sponsor
- Ultragenyx Pharmaceutical Inc